Volume 22, Number 9—September 2016
CME ACTIVITY - Research
Use of Testing for West Nile Virus and Other Arboviruses
Table 1
Variable |
No. (%) |
Baseline characteristic | |
Adult* | 567 (75) |
Male | 357 (48) |
White |
306 (41) |
Concurrent medical condition | |
Charlson Comorbidity Index score >1 | 70 (9) |
HIV infection |
42 (6) |
Clinical features | |
Encephalitis† | 237 (32) |
Illness onset during West Nile virus season‡ |
390 (52) |
Testing performed | |
West Nile virus serology | 281 (37) |
Other arbovirus serology | 174 (23) |
Magnetic resonance imaging of brain |
290 (39) |
Management and outcomes | |
Admission | 725 (97) |
Received empirical antibiotic treatment | 582 (77) |
Received empirical antiviral treatment | 193 (26) |
Adverse outcome§ |
85 (11) |
Etiologies | |
Unknown | 518 (69) |
Viral | 160 (21) |
Enterovirus | 63 (8) |
Herpes simplex virus | 48 (6) |
West Nile virus | 32 (4) |
Other¶ | 17 (2) |
Bacterial# | 43 (6) |
Fungal** | 15 (2) |
Mycobacterium tuberculosis | 8 (1) |
Noninfectious†† | 7 (1) |
*>18 y of age. Median age 31 (range 2 mo–92 y).
†Possible, probable or confirmed diagnosis of encephalitis (13).
‡Jun–Oct.
§Glasgow Outcome Scale score 1-4 (14 ).
¶Varicella zoster virus (n = 7), St. Louis encephalitis virus (n = 3), acute HIV infection (n = 3), cytomegalovirus (n = 2), Epstein-Barr virus (n = 1), influenza virus (n = 1).
#Streptococcus pneumoniae (n = 15), Mycoplasma pneumoniae (n = 5), Staphylococcus aureus (n = 3), Streptococcus agalactiae (n = 3), Haemophilus influenzae n = 3), Escherichia coli (n = 3), Listeria monocytogenes (n = 2), Enterococcus spp. (n = 2), Neisseria meningitides (n = 2), α-hemolytic Streptococcus (n = 1), Streptococcus pyogenes (n = 1), coagulase-negative Staphylococcus (n = 1), Brucella sp. (n = 1), Treponema pallidum (n = 1).
**Cryptococcus neoformans (n = 14), Histoplasma capsulatum (n = 1).
††Malignancies (n = 3), systemic lupus erythematosus (n = 1), sarcoidosis (n = 1), acute disseminated encephalomyelitis (n = 1), cerebral aneurysm (n = 1).